NASDAQ · CYRX

CryoPort, Inc.

$15.15 -$0.22 (-1.43%) 1D After hours

Key Metrics

$774.68M
Market cap
9.72×
P/E · TTM
$182.94M
Revenue · TTM
$79.74M
Net income
EPS · TTM $1.60
Dividend yield
Free cash flow −$23.76M
Beta · 1Y 1.68
EBITDA · TTM −$6.23M
Gross margin 47.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 28
    The stock moved +8.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 28
  • May 5
    The stock moved +19.4% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$774.68M
Enterprise value
Shares outstanding50.4M
52-wk range$6.69 – $16.89
Avg volume · 20D533.3K
Net cash
Book value / share$9.91
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About CryoPort, Inc.
IPO dateJul 16, 1993
Employees738

CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E9.72
P/S4.23
P/FCF
EV/EBITDA
EV/Sales
Graham №$18.87

Profitability

Gross 47.2%
Operating -17.9%
Net 43.6%
FCF -13.0%
ROE / ROIC 17.8% · -37.6%

Financial Health

Current ratio2.09
Quick ratio2.00
Debt / equity
Debt / EBITDA
Net cash
Working capital$245.67M

Cash Flow · TTM

Operating CF −$503.00K
Capex −$23.25M
Free cash flow −$23.76M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

0.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$18.87 vs $15.15
Trades below classic defensive value — Graham-cheap
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings